The complaint alleges that GeneDx issued materially false and misleading statements to the market throughout the class period. The core of the litigation centers on the company’s Q1 2026 performance, which revealed a significant drop in adjusted gross margins and forced a downward revision of full-year earnings projections. According to the lawsuit, these disclosures contradicted the company’s previous public assurances.
Investors Target GeneDx Holdings in Securities Class Action
A federal class action lawsuit now challenges GeneDx Holdings Corp. for alleged violations of the Securities Exchange Act, following a period where the company reportedly misled shareholders regarding its financial health. Investors who purchased WGS stock between April 16, 2025, and May 4, 2026, face an August 3, 2026, deadline to participate.
Legal counsel from the DJS Law Group is currently soliciting investors who suffered financial losses to act as potential lead plaintiffs. While participation in the recovery process does not mandate a formal lead plaintiff appointment, the firm highlights the necessity of aggressive advocacy for shareholders impacted by the stock's volatility during the period in question. David J. Schwartz of DJS Law Group is managing inquiries for those seeking to join the action.
Comments (0)
No comments yet. Be the first!